Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth - 2In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- 3Syrian army says recent drone attacks targeted its bases near Iraq, most shot down
- 4German inflation soars to 2.7% in March as Iran war drives up prices
- 5Dependable Savvy Locks to Update Your Home Security
- Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
- Grasping the Qualifications Among Separation and Dissolution
- With Obamacare premium hikes, more people opting for no coverage or cheaper plans
- Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
- Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
- Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- Germany's Lufthansa enters race for stake in Portuguese airline TAP
- Hezbollah sees potential win as Israel backs down from disarmament goal
